David P. Labbé

This study identifies iron metabolism as a therapeutic target in stem cell-like castration-resistant prostate cancer by showing that inhibiting NRF2 induces ferroptosis in CD44hi cells.

This paper identifies the EZH2-TTP-mTORC1 axis as a driver of phenotypic plasticity and therapeutic vulnerability in prostate cancer, showing that combined inhibition of EZH2 and PI3K/mTORC1 improves anti-tumor activity.

This study shows MYC overexpression disrupts AR transcriptional pause release, promoting aggressive prostate cancer progression.